Beractant, surrounded by devices for its application. | |
Clinical data | |
---|---|
Pronunciation | Curosurf, Survanta, others |
Other names | Beractant, Poractant alfa, others |
AHFS/ Drugs.com | Monograph |
License data | |
ATC code | |
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII |
Pulmonary surfactant is used as a medication to treat and prevent respiratory distress syndrome in newborn babies. [1]
Prevention is generally done in babies born at a gestational age of less than 32 weeks. [1] It is given by the endotracheal tube. [1] Onset of effects is rapid. [2] A number of doses may be needed. [2]
Side effects may include slow heart rate and low oxygen levels. [1] Its use is also linked with intracranial bleeding. [1] Pulmonary surfactant may be isolated from the lungs of cows or pigs or made artificially. [1] [3] [4]
Pulmonary surfactant was discovered in the 1950s and a manufactured version was approved for medical use in the United States in 1990. [3] It is on the World Health Organization's List of Essential Medicines. [5]
Pulmonary surfactant is used to treat and prevent respiratory distress syndrome in newborn babies. [1] Prevention is generally done in babies born less than 32 weeks gestational age. [1] Tentative evidence supports use in drowning. [6]
Surfactant administration can also be effective in meconium aspiration syndrome where it has been shown to help lower length of stay. [7] [8]
For patients with acute respiratory distress syndrome (ARDS), surfactant has not been shown to reduce mortality. However, it may be beneficial in those with COVID-19 associated ARDS. [9] [10]
There are a number of types of pulmonary surfactants available. Like their natural counterparts, pulmonary surfactant preparations consist of phospholipids (mainly DPPC) combined with spreading agents such as SP-B and SP-C. [11] Ex-situ measurements of surface tension and interfacial rheology can help to understand the functionality of pulmonary surfactants. [12]
Synthetic pulmonary surfactants:
Animal-derived surfactants:
Researcher John Clements identified surfactants and their role in the 1950s. Mary Ellen Avery soon after showed that the lungs of premature infants could not produce surfactants. [15]
Exosurf, Curosurf, Infasurf, and Survanta were the initial surfactants FDA approved for use in the U.S. [16]
In 2012, the US FDA approved an additional synthetic surfactant, lucinactant (Surfaxin). [17]
Beractant, surrounded by devices for its application. | |
Clinical data | |
---|---|
Pronunciation | Curosurf, Survanta, others |
Other names | Beractant, Poractant alfa, others |
AHFS/ Drugs.com | Monograph |
License data | |
ATC code | |
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII |
Pulmonary surfactant is used as a medication to treat and prevent respiratory distress syndrome in newborn babies. [1]
Prevention is generally done in babies born at a gestational age of less than 32 weeks. [1] It is given by the endotracheal tube. [1] Onset of effects is rapid. [2] A number of doses may be needed. [2]
Side effects may include slow heart rate and low oxygen levels. [1] Its use is also linked with intracranial bleeding. [1] Pulmonary surfactant may be isolated from the lungs of cows or pigs or made artificially. [1] [3] [4]
Pulmonary surfactant was discovered in the 1950s and a manufactured version was approved for medical use in the United States in 1990. [3] It is on the World Health Organization's List of Essential Medicines. [5]
Pulmonary surfactant is used to treat and prevent respiratory distress syndrome in newborn babies. [1] Prevention is generally done in babies born less than 32 weeks gestational age. [1] Tentative evidence supports use in drowning. [6]
Surfactant administration can also be effective in meconium aspiration syndrome where it has been shown to help lower length of stay. [7] [8]
For patients with acute respiratory distress syndrome (ARDS), surfactant has not been shown to reduce mortality. However, it may be beneficial in those with COVID-19 associated ARDS. [9] [10]
There are a number of types of pulmonary surfactants available. Like their natural counterparts, pulmonary surfactant preparations consist of phospholipids (mainly DPPC) combined with spreading agents such as SP-B and SP-C. [11] Ex-situ measurements of surface tension and interfacial rheology can help to understand the functionality of pulmonary surfactants. [12]
Synthetic pulmonary surfactants:
Animal-derived surfactants:
Researcher John Clements identified surfactants and their role in the 1950s. Mary Ellen Avery soon after showed that the lungs of premature infants could not produce surfactants. [15]
Exosurf, Curosurf, Infasurf, and Survanta were the initial surfactants FDA approved for use in the U.S. [16]
In 2012, the US FDA approved an additional synthetic surfactant, lucinactant (Surfaxin). [17]